For many cancer patients, conventional forms of chemotherapy are only partially successful due to their unspecific mode of action and their toxic side-effects. Innovative cell biological procedures involving the activation of tumour-specific T cells using dendritic cell therapy are possible alternatives. Dendritic cells are loaded or activated with tumour-associated antigens (RNA or proteins/peptides). The cells are then returned to the cancer patients in order to achieve in vivo a strong stimulation of tumour-specific cytotoxic and helper T cells, which attack and destroy the tumour. In a project conducted in collaboration with Life Research Technologies (LRT) GmbH, we have improved existing experimental strategies as well as developed new methods for the detection and quantification of the activity profiles of immune cells, in parallel with clinical studies.
Development of new methods for improving oncological immunotherapy procedures
Department of Life Sciences
- Further Information
- Status: Completed
- Project ID : 377
- Project Leader
- Prof.(FH) Priv.Doz. Mag. Dr. Andreas EgerHead of Research Institute Applied Bioanalytics & Drug Development / Professor Department of Life Sciences